RecruitingNot Applicable

Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

Russia336 participantsStarted 2023-02-01

Plain-language summary

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-85 ; * Diagnosis of acute ischemic stroke eligible for thrombolytic therapy; * Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed. Exclusion Criteria: * Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase; * The presence of a contraindication to thrombolytic therapy of ischemic stroke; * Pregnancy or lactation.

What they're measuring

Proportion of intracerebral hemorrhage

Timeframe: 36 hours

Trial details

NCT IDNCT05697575

SponsorNational Society for Neurosonology and Cerebral Circulation

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-02-01

Contact for this trial

Tatiana Kharitonova

+79217450431 tvh2001@mail.ru

View on ClinicalTrials.gov More Acute Stroke trials